ホーム>>Nucleotides/Nucleosides>>5-(Hydroxymethyl)-2'-deoxyuridine

5-(Hydroxymethyl)-2'-deoxyuridine

カタログ番号GC40527

5-(ヒドロキシメチル)-2'-デオキシウリジンは、抗がん作用および抗ウイルス作用を持つヌクレオシドアナログです。

Products are for research use only. Not for human use. We do not sell to patients.

5-(Hydroxymethyl)-2'-deoxyuridine 化学構造

Cas No.: 5116-24-5

サイズ 価格 在庫数 個数
10mg
$34.00
在庫あり
25mg
$81.00
在庫あり
50mg
$153.00
在庫あり
100mg
$260.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

5-(Hydroxymethyl)-2'-deoxyuridine is a nucleoside analog with anticancer and antiviral activities. It inhibits the replication of murine S180 lung carcinoma cells and Ehrlich ascites mammary carcinoma cells (ED50s = 8.5 and 4 μM, respectively) and multiple human leukemia cell lines (IC50s = 1.7-5.8 μM). 5-(Hydroxymethyl)-2'-deoxyuridine acts synergistically with 5-fluorouracil against HT-29, HCT116, PANC-1, and EKVX cancer cells with no effect on WI38 embryonic lung fibroblasts. It inhibits herpes simplex virus type 1 (HSV-1) pyrimidine 2'-deoxyribonucleoside kinase (Ki = 3.5 μM) and reduces HSV-1 viral titer to 0.05% of the control at a concentration of 200 μM. 5-(Hydroxymethyl)-2'-deoxyuridine is also a DNA adduct, formed in response to oxidative stress, that is found in hepatic DNA of rats treated with gamma irradiation, diethylnitrosamine, 2-acetylaminofluorene, and ciprofibrate .

レビュー

Review for 5-(Hydroxymethyl)-2'-deoxyuridine

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 5-(Hydroxymethyl)-2'-deoxyuridine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.